SWAGÊÓƵ

• Rajiv Academy for Pharmacy, Mathura, India; B. Pharm; Date of Completion: 09/2003; Field of study: Pharmaceutical Sciences
• St. John’s University College of Pharmacy and Allied Health Professions, Queens, NY; M.S; Date of Completion: 05/2008; Field of study: Pharmacology
• St. John’s University, College of Pharmacy and Allied Health Professions, Queens, NY; Ph.D; Date of Completion: 06/2014; Field of study: Pharmacology

• Associate Professor, College of Veterinary Medicine, Western University, Pomona, CA; Nov 2023-Present
• Associate Professor, College of Pharmacy, Marshall B. Ketchum University, Fullerton, CA; Aug 2018-Nov 2023
• Assistant Professor, Touro College of Pharmacy, NY; Aug 2014-July 2018

Pharmacology Education Scholarship of Teaching and Learning

Interdisciplinary pharmacology: covering aspects of human and veterinary pharmacology Developing CME/CE webinar series

PBL Session Facilitator VBS Pharmacology

Interdisciplinary research examining the effects of addiction on neurological disorders, drug addiction treatment, lifestyle modifications. Interdisciplinary research infections that have implications for both human and veterinary medicine.

Designed and developed CME/CE webinar series on pharmacogenomics for health care providers, in collaboration with New York Medical College, NY (Funded by Admira Health): 2016 Impact of Pharmacogenomic testing on Physicians’ Prescribing of Chronic Pain Medications (Funded by Premier DNA): 2016

Faculty Research Award (Touro College of Pharmacy, NY; 2015)

• Veterinary Information Network (VIN)
• American Association of Veterinary Medical Colleges (AAVMC)
• American Society of Experimental Pharmacology (ASPET)
• American Association of Colleges of Pharmacy (AACP)

Papers:

• Dahiya, R., Dahiya, S., Kumar, P., Kumar, R. V., Dahiya, S., Kumar, S., Saharan, R., Basu, P., Mitra, A., Sharma, A., Kashaw, S. K., Patel, J. K. Structural and biological aspects of natural bridged macrobicyclic peptides from marine resources. Arch. Pharm. 2021, 354, e2100034.
• Li, J; Kumar, P; Anreddy, N; Zhang, Y.K; Wang, Y.J; Chen, Y; Talele, T.T; Gupta, K; Trombetta, L.D; Chen, Z.S. 2017. Quizartinib (AC220) reverses ABCG2-mediated multidrug resistance: In vitro and in vivo studies. Oncotarget. 16;8(55):93785-93799. doi: 10.18632/oncotarget.21078.
• Anreddy, N; Patel, A; Zhang, Y.K; Wang, Y.J; Shukla, S; Kathawala, R.J; Kumar, P; Gupta, P; Ambudkar, S.V; Wurpel, J.N.D; Chen, Z.S; Guo, H. 2015. A-803467, a tetrodotoxin-resistant sodium channel blocker, modulates ABCG2-mediated MDR in vitro and in vivo. Oncotarget • Kumar, P; Basu, P; Knapp, K. 2015. Overview of Ebola Outbreak Stresses Proactive Solutions. Commentary. Medscape
• Sun, Y. L., Kumar, P., Sodani, K., Patel, A., Pan, Y., Baer, M. R., Chen, Z. S., W. Q, J. 2014. Ponatinib enhances anticancer drug sensitivity in MRP7-overexpressing cells. Oncol. Rep 31 (4), 1605-1612
• Sodani, K., Patel, A., Anreddy, N., Singh, S., Yang, D. H., Kathawala, R. J., Kumar, P., Talele, T. T., Chen, Z. S. 2014. Telatinib reverses chemotherapeutic multidrug resistance mediated by ABCG2 efflux transporter in vitro and in vivo. Biochem. Pharm 89 (1), 52-61
• Wang, Y. J., Kathawala, R. J., Zhang, Y. K., Patel, A., Kumar, P., Shukla, S., Fung, K. L., Ambudkar, S. V., Talele, T. T., Chen, Z. S., 2014. Motesanib (AMG706), a potent multikinase inhibitor, antagonizes multidrug resistance by inhibiting the efflux activity of the ABCB1. Biochem. Pharmacol 90 (4), 367-78
• Sun, Y. L., Chen, J. J., Kumar, P., Chen, K., Sodani, K., Patel, A., Chen, Y. L., Chen, S. D., Jiang, W. Q., Chen, Z. S. 2013. Reversal of MRP7 (ABCC10)-Mediated Multidrug Resistance by Tariquidar. PLoS One. 8(2), e55576 • Kumar, P., Zhang, D. M., Degenhardt, K., Chen, Z. S., 2012. Autophagy and transporter based multi drug resistance. Cells. 1(3), 558-575 • Sun, Y. L., Patel, A., Kumar, P., Chen, Z. S., 2012. Role of ABC transporters in cancer chemotherapy. Chin. J. Cancer. 31(2), 51-7
• Kumar, P., Sunkarneni, S., Sirohi, S., Dighe, S. V., Walker, E. A., Yoburn, B. C., 2008. Hydromorphone efficacy and treatment protocol impact on tolerance and μ-opioid receptor regulation. Eur. J. Pharm. 597, 39-45 • Sirohi, S., Kumar, P., Yoburn, B. C., 2007. µ-opioid receptor up-regulation and functional supersensitivity are independent of antagonist efficacy. J. Pharm. Exp. Ther. 323, 701-707
• Pawar, M., Kumar, P., Sunkaraneni, S., Sirohi, S., Walker, E. A., Yoburn, B. C., 2007. Opioid agonist efficacy predicts the magnitude of tolerance and the regulation of μ-opioid receptors and dynamin-2. Eur. J. Pharm. 563, 92-101

Book Chapters:

• Basu P, Garcia J, Kumar P. Emergence of antimicrobial resistance in hospitals. (2021). Book Chapter in Practical Handbook of Microbiology 4th ed ISBN9781003099277. CRC Press
• Vadlapatla R, Wang Z, Kumar P, Pavuluri N. 2020. Use of physical approaches for systemic drug delivery. Book chapter in Healthy Ageing and Longevity, Vol 13. ISBN 978-3-030-54490-4. Springer Nature
• Basu, P; Vadlapatla, R; Kumar, P; Gray, J. P. 2019. Misc. Medical devices and technologies. Side Effects of Drugs Annual, Vol 41. ISBN: 0378-6080. Elsevier B. V
• Huang, X., Kumar, P., Anreddy, N., Xiao, X., Yang, D. H., Chen, Z.S. 2015. P-gp Inhibitory Activity from Marine Sponges, Tunicates and Algae. Handbook of Anticancer Drugs from Marine Origin 1, 593-619, Springer. Doi: 10.1007/978-3-319-07145-9_28

Dr. Kumar is a dedicated academic professional whose career seamlessly blends teaching, research, and service in the field of interdisciplinary pharmacology. Since joining academia, Dr. Kumar has demonstrated strong leadership and a steadfast commitment to educational excellence. He has actively participated in various professional committees, contributing to the advancement of pharmacology education and shaping its landscape. In addition to his involvement in pharmacology education, Dr. Kumar has played a pivotal role in fostering mentorship and advocating for diversity and inclusion within the academic community. Through his efforts, he has created an environment that empowers and supports the professional development of students and colleagues from diverse backgrounds. Dr. Kumar's dedication to excellence, commitment to mentorship, and advocacy for diversity and inclusion continue to inspire and empower the next generation of healthcare professionals and researchers, encouraging them to make meaningful contributions to the field of healthcare.